ANALYSIS OF COLISTIN DISTRIBUTION IN PSEUDOMONAS AERUGINOSA BIOFILM DEGRADED BY BACTERIOPHAGES USING LASER INTERFEROMETRY METHOD

Zuzanna Drulis-Kawa 1 Michal Arabski 2 Slawomir Wasik 3
1Department of Pathogen Biology and Immunology, University of Wroclaw, Wroclaw
2Department of Microbiology, Jan Kochanowski University, Kielce
3Department of Molecular Physics, Jan Kochanowski University, Kielce

Biophysical properties of biofilm structure (exopolysaccharide matrix) associated with reduced susceptibility to antibiotics limits the effective eradication of bacteria, for example, Pseudomonas aeruginosa in cystic fibrosis. It is suggested that only the surface layers of biofilm is exposed to a lethal dose of the antibiotic due to diffusion barrier. The efficient eradication of bacteria forming biofilm may be supported by lytic bacteriophages enable to degrade bacterial exopolysaccharide matrix. The quantitative measurements of colistin diffusion through biofilm and antibiotic concentration in biofilm after phage application were measured by laser interferometry system. It consisted of a Mach-Zehnder interferometer with He-Ne laser, membrane elements (place of biofilm formation), TV-CCD camera and software for interference images acquisition and processing. The interferograms were recorded from 120 to 2400 s with a time interval of Δt = 120 s and the profiles for colistin were constructed. Profiles served for calculation of the colistin amount transported through biofilm in function of time (N(t)). In the same assay the amount of colistin distributed in biofilm was determined. The level of P. aeruginosa biofilms eradication by bacteriophages and/or colistin were determined by microscopic pictures analysis after crystal violet or methylene blue staining using imageJ software.

This work was supported by grant 2012/04/M/NZ6/00335 from the National Science Centre, Poland. Michal Arabski and Zuzanna Drulis-Kawa acknowledge COST Action BM1003 "Microbial cell surface determinants of virulence as targets for new therapeutics in Cystic Fibrosis".








 




Powered by Eventact EMS